Showing results (271-280 of 301) with videos related to

Sort By:
Pageof 31
Arteriosclerosis, Thrombosis, and Vascular Biology|July 3, 2025
LDL-Bound PCSK9 Has a Slower Clearance Kinetic and Higher Use for HSPGs Than Free-PCSK9-Brief ReportSilvia Cecilia Pacheco-Velázquez, Carlota Oleaga, Bastian Ramms, et al.
Scientific Reports|January 12, 2021
Role of PAI-1 in hepatic steatosis and dyslipidemiaJoshua A Levine, Carlota Oleaga, Mesut Eren, et al.
Diabetes Care|February 6, 2025
Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized TrialGregory G Schwartz, Michael Szarek, J Wouter Jukema, et al.
Circulation. Cardiovascular Genetics|March 26, 2016
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH RegistryEmil M deGoma, Zahid S Ahmad, Emily C O'Brien, et al.
The New England Journal of Medicine|April 13, 2017
Autoantibodies against GPIHBP1 as a Cause of HypertriglyceridemiaAnne P Beigneux, Kazuya Miyashita, Michael Ploug, et al.
Blood|July 28, 2023
Low-density lipoprotein promotes microvascular thrombosis by enhancing von Willebrand factor self-associationDominic W Chung, Kimsey Platten, Koya Ozawa, et al.
European Heart Journal|May 25, 2026
Interleukin-6 and C-reactive protein prognostic value following acute coronary syndromeJohan Wouter Jukema, Nicolaas J Van Neer, Michael Szarek, et al.
Journal of the American College of Cardiology|April 25, 2006
Metabolic syndrome and the risk of cardiovascular disease in older adultsJaved Butler, Nicolas Rodondi, Yuwei Zhu, et al.
Journal of the American Heart Association|August 23, 2025
Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES TrialGregory P Geba, Kusha A Mohammadi, Amy Damask, et al.
European Journal of Preventive Cardiology|February 8, 2025
Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndromeGregory G Schwartz, Michael Szarek, Esther Reijnders, et al.
Pageof 31